Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Max Qian"'
Autor:
Abdel Saci, Akintunde Bello, Rui Wang, Megan Wind-Rotolo, Max Qian, Yan Feng, Fareeda Hosein, Jasmine I. Rizzo, Junying Zheng, Xiao Shao, Amit Roy, Rebecca A. Moss, Irene Pak
Publikováno v:
Cancer Research. 79:2273-2273
Background: Data suggest that peripheral factors such as circulating cytokines could function as predictive indicators of clinical response to specific therapies or as general prognostic indicators of outcome in patients with cancer. Previous studies
Autor:
Jasmine I. Rizzo, Donald G. Jackson, F. Stephen Hodi, Jedd D. Wolchok, Han Chang, Sujaya Srinivasan, James Larkin, Tina C. Young, Megan Wind-Rotolo, Dirk Schadendorf, Max Qian, Abdel Saci, Paolo A. Ascierto
Publikováno v:
Cancer Research. 79:CT037-CT037
Background: Increased tumor mutational burden (TMB) and inflammation are associated with improved clinical outcomes to immuno-oncology (I-O) therapy in many tumor types. Genomic correlates of response to nivolumab (N) vs dacarbazine (D) (CheckMate [C
Autor:
Jedd D. Wolchok, Jeffrey S. Weber, Megan Wind-Rotolo, Andressa S. Laino, Max Qian, Hao Tang, F. Stephen Hodi, Mario Sznol, James Larkin, Caroline Robert, Lauren Hippeli, David M. Woods
Publikováno v:
Journal of Clinical Oncology. 37:100-100
100 Background: Acute phase reactants including C-reactive protein (CRP), and chronic inflammatory proteins including IL-6, which induces production of CRP from the liver, have been associated with a poor outcome in a variety of cancers. Methods: Ser
Autor:
Keith Stockerl-Goldstein, Max Qian, Syed Rizvi, Richy Agajanian, David S. Siegel, Giampaolo Talamo, Weiyuan Chung, Nizar J. Bahlis, Shankar Srinivasan, Frederic J. Reu, Gary J. Schiller, Anjan Thakurta, Hakan Kaya, Michael Sebag, Jorge Mouro, Ehsan Malek, Kevin W. Song
Publikováno v:
Journal of Clinical Oncology. 35:8027-8027
8027 Background: Recent trials of triple therapy in 2L and third-line (3L) Tx excluded pts refractory to LEN. This is not reflective of standard of care in first line and 2L where LEN is given until progressive disease (PD). MM-014 enrolled pts with
Autor:
Frederic J. Reu, Weiyuan Chung, Kevin W. Song, Nizar J. Bahlis, Hakan Kaya, Gary J. Schiller, Keith Stockerl-Goldstein, Max Qian, Eshan Malek, Michael Sebag, Shankar Srinivasan, David S. Siegel, Anjan Thakurta, Richy Agajanian, Syed Rizvi, Jorge Mouro
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:e141
Autor:
Keith Stockerl-Goldstein, Richy Agajanian, Max Qian, Weiyuan Chung, Nizar J. Bahlis, Fred Reu, Jorge Mouro, Ehsan Malek, Syed Rizvi, Anjan Thakurta, David S. Siegel, Gary J. Schiller, Hakan Kaya, Kevin W. Song, Michael Sebag, Shankar Srinivasan
Publikováno v:
Blood. 128:4497-4497
Background: Pomalidomide (POM) in combination with low-dose dexamethasone (LoDEX) is approved for the treatment (Tx) of patients (pts) with multiple myeloma (MM) who have had ≥ 2 prior lines of therapy, including lenalidomide (LEN) and a proteasome
Autor:
Javier Lluch, Jose Freire, Teresa Peiró, Patricia Almudever, Javier Milara, Adele Serrano, Julio Cortijo, Max Qian
Publikováno v:
A110. EMERGING INSIGHTS INTO OBSTRUCTIVE LUNG DISEASE: LATE BREAKING ABSTRACTS.
Autor:
Patricia Almudever, Teresa Peiró, Julio Cortijo, Javier Lluch, Max Qian, Javier Milara, Jose Freire, Adela Serrano
Publikováno v:
Chest. 142:663A
Autor:
Le, Huy1 (AUTHOR), Peng, Beverly1 (AUTHOR), Uy, Janelle1 (AUTHOR), Carrillo, Daniel1 (AUTHOR), Zhang, Yun2 (AUTHOR), Aevermann, Brian D.2 (AUTHOR), Scheuermann, Richard H.2,3,4 (AUTHOR) rscheuermann@jcvi.org
Publikováno v:
PLoS ONE. 9/23/2022, Vol. 17 Issue 9, p1-15. 15p.
Autor:
Murugan, Baranya, Sagadevan, Suresh, J, Anita Lett, Fatimah, Is, Fatema, Kamrun Nahar, Oh, Won-Chun, Mohammad, Faruq, Johan, Mohd Rafie
Publikováno v:
Materials Research Express; Oct2020, Vol. 7 Issue 10, p1-14, 14p